medigraphic.com
ISSN 1405-8871 (Print)

2023, Number 3

<< Back Next >>

Aten Fam 2023; 30 (3)

Clinical-Epidemiologic Characterization of Patients with Breast Cancer in a Family Medicine Unit

Sosa-Martínez MJ, Urbina-Aranda II, Ramírez-Ríos R, Ocampo-Rentería T, Espino-Rodríguez Y, Pérez-Saldívar ML

Language: Spanish
References: 37
Page: 206-211
PDF size: 147.55 Kb.


ABSTRACT

Objective: analyze the clinical-epidemiological characterization of patients with breast cancer in the Family Medicine Unit (UMF) No. 9, of the Mexican Institute of Social Security (IMMS) in Acapulco, Mexico from 2018 to 2021. Methods: cross-sectional, descriptive, retrospective study which included 71 patients with a positive diagnosis of breast cancer, assigned to the fmu No. 9, in Acapulco, Mexico, from 2018 to 2021. The studied population was obtained from the Institutional Cancer Registry of the Epidemiology system; the source of information was the electronic clinical record, from which clinical-epidemiological information, mammography report, histopathological result, and clinical stage were collected. Descriptive statistics were performed using simple frequencies and percentages with the obtained data. Results: 46.4% (33/71) of breast cancer cases were registered in 2018. 32.4% were 61-70 years old, 98.6% were women, 42.3% were overweight, and 31.0% had type 2 diabetes mellitus (DM2). According to the BI-RADS (B) classification, 38.0% presented a b4. Regarding the histopathological report, ductal carcinoma was the most common with 76.1% (54/71). Conclusions: a significant percentage of breast cancer was detected in patients who were overweight, and had type 2 diabetes mellitus, nearly 40% of the patients had lesions of intermediate suspicion of malignancy, while three quarters of the patients presented with ductal carcinoma. It is extremely important to strengthen the primary care level through health promotion, and encourage breast and clinical self-examination during the first medical contact to detect risk factors and clinical signs suggestive of the disease, which will reduce morbidity and mortality.


REFERENCES

  1. Yazdani-Charati R, Hajian-Tilaki K, SharbatdaranM. Comparison of pathologic characteristics ofbreast cancer in younger and older women. CaspianJ Intern Med. 2019; 10(1):42-47.

  2. Bernal-Salazar MJ, González HC, López-SánchezNL, Juárez-Lira A, Mancera-Roque H, Hernández-Castañón MA, et al. Asociación del cáncer demama con síndrome metabólico y estado nutricionalen mujeres en Querétaro, México. Rev Actualizaciónen Nutrición. 2016;17(4):102-108.

  3. Organización Panamericana de la Salud (OPS).Cáncer de mama [Internet]. [Citado 2023 Ene 5].Disponible en: https://www.paho.org/es/temas/cancer-mama

  4. Ferlay J, Colombet M, Soerjomataram I, MathersC, Parkin D, Piñeros M, et al. Estimating theglobal cancer incidence and mortality in 2018:GLOBOCAN sources and methods. Int J Cancer.2019;144(8):1941-1953.

  5. Osorio-Bazar N, Bello-Hernández C, Vega-BazarL. Factores de riesgo asociados al cáncer de mama.Rev Cubana Med Gen Integr. 2020;36(2):1-6.

  6. Palacio-Mejía LS, Lazcano-Ponce E, Allen-LeighB, Hernández-Ávila M. Diferencias regionalesen la mortalidad por cáncer de mama y cérvix enMéxico entre 1979 y 2006. Salud Pública Mex.2009;51(Suppl.2):208-219.

  7. Instituto Nacional de Estadística y Geografía(INEGI). Estadísticas a propósito del día mundialde la lucha contra el cáncer de mama [Internet].[Citado 2021 junio 16]. Disponible en: https://www.inegi.org.mx/contenidos/saladeprensa/aproposito/2020/Cancermama20.pdf

  8. Instituto Mexicano del Seguro Social. Guía Técnicapara la Atención Integral del Cáncer de Mama[Internet]. [Citado 2021 Jul 26]. Disponibleen: https://imsssalinacruzoaxaca.files.wordpress.com/2019/11/guc3ada-cama_2019.pdf

  9. Secretaria de Salud. Norma Oficial MexicanaNOM-041-SSA2-2011 [Internet]. [Citado 2021Jul 26]. Disponible en: http:www.salud.gob.mx/unidades/cdi/nom/041ssa202.html

  10. Bhattacharjee A, Bhattacharyya T, Thomas A. Humanepidermal growth factor receptor 2 borderlinemortality in breast cancer patients: evidencefrom surveillance, epidemiology, and end resultsprogram population-based study. Clin EpidemiolGlobal Health. 2018;6(2):88–93.

  11. Bertehelli-Carona I, Ángeles-Casas M, Mejía-MirandaN, Martínez Ángeles, J. Obesidad en mujerescon cáncer de mama en un hospital generalde zona de Hidalgo, México. Atención Familiar.2018;25(1):3-6.

  12. División de Prevención y Control del Cáncer, Centrospara el Control y la Prevención de Enfermedades[Internet]. [Citado 2021 junio 16]. Disponibleen: https://www.cdc.gov/spanish/cancer/breast/basic_info/risk_factors.htm

  13. World Health Organization. Cáncer de mama [Internet][Consultado 2021 junio 16]. Disponibleen: https://www.who.int/news-room/fact-sheets/detail/breast-cancer

  14. Durruthy LS, Toirac RR, Rubio-Hernández MC,Fitz AT, Camejo YC, Madruga TG. Factores deRiesgo reproductivo en pacientes con cáncer demama. Rev Archivo del Hospital Universitario“Calixto García”. 2017;5(1):13-19.

  15. Adeloye D, Sowunmi OY, Jacobs W, David RA,Adeosun AA, Amuta AO, et al. Estimating theincidence of breast cancer in Africa: a systematicreview and meta-analysis. J Glob Health.2018;8(1):010419.

  16. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-TieulentJ, Jemal A. Global cancer statistics, 2012. CACancer J Clin. 2015;65(2):87–108

  17. Ferlay J, Soerjomataram I, Dikshit R, Eser S,Mathers C, Rebelo M, Parkin DM, Forman D,Bray F. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN2012. Int J Cancer. 2015;136(5):E359-86.

  18. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidenceand Mortality and Epidemiology of BreastCancer in the World. Asian Pac J Cancer Prev.2016;17(S3):43–46.

  19. Guía de Práctica Clínica: Tratamiento del cáncer demama en segundo y tercer nivel de atención [Internet].[Citado 2021 junio 16]. Disponible en: imss.gob.mx/sites/all/statics/guiasclinicas/232GER.pdf

  20. Ramos-Águila YC, Marimón-Torres ER, Crespo-González C, Junco-Sena B, Valiente-Morejon W.Cáncer de mama, su caracterización epidemiológica.Rev Ciencias Médicas. 2015;19(4):619-629.

  21. Solano-Piza RI, Joanico-Morales B, Candelario-Cruz R, Sierra-López L, Salgado-Jiménez MA,Rodríguez-Echeverría G. Características epidemiológicas,radiológicas e histológicas de cáncer demama en usuarias de un hospital general regionalen Guerrero, México. Aten Fam. 2022;29(1):20-24.

  22. Maffuz-Aziz A, Labastida-Almendaro S, Espejo-Fonseca A, Rodríguez-Cuevas S. Característicasclinicopatológicas del cáncer de mama en una poblaciónde mujeres en México. Cirugía y Cirujanos.2017; 85(3):201–207.

  23. Ferlay J, Shin HR, Bray F, Forman D, MathersC, Parkin DM. Estimates of worldwide burden ofcancer in 2008: GLOBOCAN 2008. Int J Cancer.2010;127(12):2893-917.

  24. Ly D, Forman D, Ferlay J, Brinton LA, CookMB. An international comparison of male and femalebreast cancer incidence rates. Int J Cancer.2013;132(8):1918-1926.

  25. Instituto Nacional de Cancerología. Anuario Estadístico2010 [Internet]. [Citado 2022 Sep 4]. Disponibleen: http://www.cancer.gov.co/documentos/Anuario%20Estaditico/2010/Anuario%20Impreso_2010.pdf

  26. Abdelwahab Yousef AJ. Male Breast Cancer:Epidemiology and Risk Factors. Semin Oncol.2017;44(4):267–272.

  27. Lundqvist A, Andersson E, Ahlberg I, NilbertM, Gerdtham U. Socioeconomic inequalities inbreast cancer incidence and mortality in Europe-asystematic review and meta-analysis. Eur J PublicHealth. 2016;26(5):804–813.

  28. Cóppola F, Nader J, Aguirre R. Metabolismo delos estrógenos endógenos y cáncer de mama. RevMed Urug. 2005;21(1):15-22.

  29. Herrera-Pastrana IL, Albavera-Hernández C,Morales-Jaimes R, Ávila-Jiménez L. Característicasclínicas y epidemiológicas de cáncer de mama enun hospital general de Cuernavaca, México. AtenFam. 2021;28(2):101-105

  30. Rui L, Guijuan Z,Fengjie B, Min M, Yi M. Eugenol suppresses thedevelopment of estrogen receptor-positive precancerousbreast lesions and regulates estrogen receptor-related proteins. Acta Medica Mediterr. 2018;34(6):1821-1827.

  31. J.R. Harris, M.E. Lippman, M. Morroe, C.K.Osborne. Disease of the breast. 3.a ed, LippincottWilliams and Wilkins, (2004), pp. 47-56.

  32. Gomes C, Vieira AM, Gonçalves P, Naves W. Principaleshallazgos de los exámenes de ultrasonografíade mama y clasificación BI-RADS. Rbus- BrasilianJ Ultraso. 2020;28(28):9-12.

  33. Li J, Zhang BN, Fan JH, Pang Y, Zhang P, WangSL, et al. A Nation-Wide multicenter 10-year(1999-2008) retrospective clinical epidemiologicalstudy of female breast cancer in china. BMCCancer. 2011;11:364.

  34. Balekouzou A, Yin P, Pamatika CM, BishwajitG, Nambei SW, Djeintote M, et al. Epidemiologyof breast cancer: retrospective studyin the Central African Republic. BMC PublicHealth.2016;16(1):1230.

  35. Ramírez-Valle M, García-Montesino G, Lores-Hechevarría C, Sánchez-Azcuy Y, Márquez-HernándezC. Histología e inmunohistoquímica delcáncer de mama invasivo en la provincia de Pinardel Río. Rev. Ciencias Médicas. 2019;23(1):71-78.

  36. Shankar S, Boyanagari M, Boyanagari VK, ShankarM, Shankar-Ayyanar R. Profile of breast cancerpatients receiving government sponsored freetreatment and the associated economic costs. ClinEpidemiol Global Health. 2018;6(4):203–207.

  37. Hassanipour S, Maghsoudi A, Rezaeian S, Arab-Zozani M, Mokhtari AM, Abdzadeh E, et al. Survivalrate of breast cancer in eastern mediterraneanregion countries: a systematic review and metaanalysis.Ann Global Health. 2019;85(1):138.




2020     |     www.medigraphic.com